Company Profile

Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.

Employees

2,200

Sector

Pharmaceuticals

More about the company

24-04-19	European Commission Solicits Feedback on Vifor Pharma's Anticompetition Commitments	MT
23-05-02	CSL Vifor Announces Topline Results from Two-Year Primary Efficacy Endpoint in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis	CI
22-12-14	Court Cancels Public Shares of Vifor Pharma after Merger with CSL	MT
22-11-02	Rhythm Biosciences Expands Executive Management Team, Registers Diagnostic Blood Test With New Zealand	MT
22-10-16	Australia's CSL raises annual profit forecast on Swiss acquisition	RE
22-10-12	Global markets live: Darktrace, Intel, Twitter, Meta, Uber...
22-10-12	Vifor Pharma Gets Approval To Delist From Swiss Bourse	MT
22-09-27	Swissmedic OKs ChemoCentryx's Combo Therapy For Rare Blood Vessel Disease	MT
22-08-25	Fitch Pulls Vifor Pharma's Rating After CSL Takeover	MT
22-08-22	Vifor, Travere's Application for Rare Kidney Disease Drug Under Review in EU	MT
22-08-22	Vifor-Fresenius Medical Care JV Wins US Infringement Case Against Teva	MT
22-08-18	UK Agency Recommends Tavneos Combo for Treatment of Rare Blood Vessel Disease	MT
22-08-16	Australia biotech giant CSL reports profit dip, flags cost spiral	RE

21-12-14	Octavian Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
21-12-14	Oddo BHF Lifts Price Target on Vifor Pharma, Downgrades Recommendation to Neutral	MT
21-12-07	AlphaValue/Baader Europe Lifts Price Target on Vifor Pharma, Maintains Buy Recommendation	MT
21-11-01	Analyst recommendations: Amazon, AMD, Bank of America, Intel, Boeing...
21-09-20	Analyst recommendations: BHP, Lear, Naked Wines, Teradata, Visteon...

22-12-14	Cancellation of remaining publicly held registered shares of Vifor Pharma AG	BU
22-11-28	Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients	BU
22-11-25	Iron Deficiency Day 2022: CSL Vifor calls to take iron seriously	BU
22-10-20	Approval of extension of exemptions from SIX disclosure and publicity obligations	BU
22-10-12	Approval of delisting of Vifor Pharma AG's registered shares	BU

24-07-22	EU-Kommission verpflichtet Pharmakonzern Vifor zu Gegendarstellung
22-12-14	Vifor: l'action déclarée nulle, décotation le 23 décembre
22-12-14	Vifor-Aktien werden am 23. Dezember dekotiert
22-11-28	CSL Vifor et Fresenius obtiennent le feu vert en Chine pour Ferinject
22-10-20	Vifor toujours exempté de certaines obligations de publier

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIFOR PHARMA AG	+19.69%	+1.82%	-	-	12.27B
ELI LILLY AND COMPANY	+3.19%	+11.31%	+67.86%	+150.58%	1,263B
JOHNSON & JOHNSON	-0.73%	+3.56%	+44.51%	+85.81%	658B
ABBVIE INC.	+1.41%	+3.24%	+29.22%	+107.83%	521B
ROCHE HOLDING AG	+0.42%	+3.20%	+54.15%	+67.18%	391B
MERCK & CO., INC.	+2.18%	+2.93%	+73.30%	+45.62%	369B
NOVARTIS AG	+1.12%	+4.52%	+35.30%	+58.08%	307B
ASTRAZENECA PLC	+6.96%	+8.86%	+11.27%	+36.62%	290B
AMGEN INC.	+1.15%	+6.09%	+59.59%	+77.06%	252B
GILEAD SCIENCES, INC.	+3.06%	+9.38%	+44.11%	+119.47%	212B
Average	+3.53%	+5.90%	+46.59%	+83.14%	473.55B
Weighted average by Cap.	+1.25%	+6.60%	+50.88%	+98.31%

Vifor Pharma AG Stock OTC Markets

Stocks

GNHAY

US92674R1023

Pharmaceuticals

Latest news: Vifor Pharma AG

Analysts' recommendations: Vifor Pharma AG

Press Releases: Vifor Pharma AG

News in other languages: Vifor Pharma AG

Quotes and Performance

Other Pharmaceuticals

Company Profile